The molecular portrait of triple-negative breast cancer: the LAG3 gene single nucleotide polymorphism rs2365094 has no impact on the clinical picture

Abstract

Abstract Introduction: Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen, progesterone and human epidermal growth factor receptors. It is the one of most heterogeneous and highly-aggressive breast cancers, resulting in fast progression. In humans, the LAG3 gene is located on chromosome 12p13 and encodes an immune-regulatory molecule. LAG3 gene polymorphisms may influence the clinicopathological picture. Aim: The aim of the study was to perform a molecular analysis of LAG3 gene polymorphisms Method: The presence of single-nucleotide polymorphisms (SNPs) at rs2365094 was determined in 30 TNBC patients and 30 healthy controls using polymerase chain reaction (PCR) and commercially-available TaqMan SNP Genotyping Assays. SNP status was the compared with clinical outcome. Result: The allelic alterations in LAG3 gene SNP in rs2365094 appear to have no influence on the clinicopathological picture among TNBC patients. The carriage rate for a single allele did not differ significantly between patients and controls. Conclusion: No significant relationship was observed between rs2365094 SNP status and clinicopathological determinants. However, one aim of this work was to identify biomarkers that may serve as criteria for drug combination regimens. When used in combination with other genetic biomarkers, LAG3 gene SNP may be used for risk stratification of patients with TNBC.